Showing results (481-490 of 493) with videos related to
Sort By:
Pageof 50
Nature|April 23, 2010
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effectMin Gao, Richard E Nettles, Makonen Belema, et al.Bioorganic & Medicinal Chemistry Letters|September 11, 2012
HCV NS5A replication complex inhibitors. Part 2: investigation of stilbene prolinamidesDenis R St Laurent, Makonen Belema, Min Gao, et al.Journal of Medicinal Chemistry|January 21, 2014
Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b repliconsMakonen Belema, Van N Nguyen, Jeffrey L Romine, et al.Bioorganic & Medicinal Chemistry Letters|January 1, 2013
HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologiesOmar D Lopez, Van N Nguyen, Denis R St Laurent, et al.American Journal of Preventive Medicine|August 23, 2014
Mass media health communication campaigns combined with health-related product distribution: a community guide systematic reviewMaren N Robinson, Kristin A Tansil, Randy W Elder, et al.Journal of Medicinal Chemistry|April 12, 2013
HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activityDenis R St Laurent, Michael H Serrano-Wu, Makonen Belema, et al.The Journal of Biological Chemistry|December 3, 2010
Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activityJianying Dong, Arlene Sereno, William B Snyder, et al.ACS Medicinal Chemistry Letters|March 18, 2016
Discovery and Preclinical Evaluation of BMS-955829, a Potent Positive Allosteric Modulator of mGluR5Fukang Yang, Lawrence B Snyder, Anand Balakrishnan, et al.Bioorganic & Medicinal Chemistry Letters|May 5, 2005
Biaryl isoxazolinone antibacterial agentsClaude A Quesnelle, Patrice Gill, Stephan Roy, et al.Mabs|March 12, 2011
A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activityJianying Dong, Arlene Sereno, Dikran Aivazian, et al.Pageof 50